Pacific Biosciences Of California, Inc. (NASDAQ: PACB)

Pacific Biosciences Of California, Inc. designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome. The company operates in the life science technology sector, focusing on creating some of the world's most advanced sequencing systems. These systems provide customers with a comprehensive and accurate view of genomes, transcriptomes, and epigenomes, addressing a broad set of applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications.

The company generates revenue through the sale of its sequencing instruments, nanofluidic chips (SMRT Cells), reagents for DNA extraction, library preparation, and sequencing, as well as application-specific sequencing workflows and services. Primary products include the Revio, Vega, and Sequel sequencing systems, which are used to conduct, monitor, and analyze single-molecule biochemical reactions. Customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies. These customers either use PacBio systems in their own laboratories or send their genetic samples to third-party service providers who sequence the samples with PacBio systems and provide the sequence data back to the customer for further analysis.

• HiFi Long-Read Sequencing: This protocol is built upon the company's SMRT sequencing systems, including consumables and software, and offers customized end-to-end workflows for different sequencing applications. Highly accurate, long sequence reads simplify and accelerate data analysis algorithms, reducing the need for error correction and/or assembly, depending on the application. Customers use these platforms for a wide range of sequencing applications, including whole genome sequencing and de novo genome assembly, long-range phasing, targeted sequencing, full-length RNA and single-cell sequencing, characterization of metagenomic communities and other mixed DNA samples, viral genome sequencing, and others. The technology is also capable of detecting epigenetic markers simultaneously by analyzing the kinetics of DNA polymerization that is affected, and thereby detectable, by epigenetic markers such as 5-methylcytosine or N6-methyladenine.

• SMRT Technology: The proprietary SMRT sequencing technology enables the direct observation of DNA synthesis in real time by monitoring the activity of individual DNA polymerase molecules as they incorporate nucleotides into a growing DNA strand. Using optical nanostructures known as zero-mode waveguides (ZMWs), SMRT sequencing detects fluorescently labeled nucleotides as they are incorporated, providing a precise, single-molecule record of DNA sequence and polymerase kinetics without amplification or cloning steps. Each DNA molecule is prepared as a circularized SMRTbell template, allowing both strands of the same molecule to be sequenced multiple times. These repeated observations are combined through circular consensus sequencing (CCS) to generate highly accurate HiFi reads, typically achieving median accuracies above Q30 with average read lengths of 15–20 kilobases. The resulting data combines long-range context with base-level precision, enabling the detection of all major classes of genetic variation—including single-nucleotide variants, structural variants, tandem repeat expansions, and DNA methylation—in a single workflow.

• Revio system, Vega system, and Sequel systems: These instruments conduct, monitor, and analyze single-molecule biochemical reactions on SMRT Cell microchips. The instruments use highly sensitive imaging systems to capture fluorescent signals generated during nucleotide incorporation and translate those signals into base calls and quality scores through integrated computational analysis. The Vega and Sequel systems sequence one SMRT Cell at a time, while the Revio system can run up to four SMRT Cells simultaneously to increase throughput. All instruments feature automated pipetting and reagent handling, on-board basecalling, perform consensus read generation, barcode demultiplexing, and methylation analysis, reducing the need for external computing resources. Together, these capabilities deliver fast, highly accurate, and efficient sequencing for applications ranging from large-scale population studies to focused translational research.

• HiFi Consumables: Customers purchase proprietary consumable products to run their PacBio systems, including SMRT Cells and reagent kits. Typically, one SMRT Cell is consumed per sequencing reaction, and scientists can choose the number of SMRT Cells they use per experiment. The company offers several reagent kits, each designed to address a specific step in the core sequencing workflow. A library preparation kit is used to convert DNA into SMRTbell double-stranded DNA library formats and includes typical molecular biology reagents, such as ligase, buffers, and exonucleases. Binding/polymerase kits include modified DNA polymerase and are used to bind SMRTbell libraries to the polymerase in preparation for sequencing. Core sequencing kits contain reagents required for on-instrument, real-time sequencing, including phospholinked nucleotides. Kinnex kits with companion SMRT Link software enable high-throughput, scalable, cost-effective RNA applications including bulk RNA, single-cell RNA, and 16S rRNA sequencing. The Kinnex kits use a molecular concatenation approach to link smaller amplicons into longer fragments for sequencing on PacBio long-read systems, significantly increasing molecular yield. PureTarget panels and reagent kits for targeted sequencing applications, including repeat expansion analysis and carrier screening, leverage HiFi sequencing accuracy to detect complex variants and repeat expansions with single-molecule resolution, enabling efficient, scalable targeted analysis.

Pacific Biosciences Of California, Inc. operates in a competitive industry with several key players, including Illumina, BGI Genomics (also known as MGI or Complete Genomics), Thermo Fisher Scientific Inc. (Thermo), Oxford Nanopore Technologies Ltd. (ONT Ltd.), Roche Holding AG (Roche), Qiagen N.V. (Qiagen), Element Biosciences, Inc. (Element), Bionano Genomics, Inc. (Bionano), Ultima Genomics, Inc. (Ultima), and 10x Genomics, Inc. (10x). These companies may have different levels of financial, technical, manufacturing, administrative, and support resources available to them. The company's competitive advantages lie in its HiFi long-read sequencing technology, which delivers high consensus accuracy and long-read lengths, includes single-molecule, real-time resolution, detects real-time kinetic information, provides fast time-to-result and flexibility, and supports the breadth and depth of current and future applications. The company's focus on creating some of the world's most advanced sequencing systems positions it as a leader in the genomics solutions market.

The company's customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, CROs, pharmaceutical companies, and agricultural companies. These customers isolate, prepare, and analyze genetic samples using PacBio systems in their own laboratories, or send their genetic samples to third-party service providers who in turn sequence the samples with PacBio systems and provide the sequence data back to the customer for further analysis. The company receives a significant portion of its revenue from a limited number of customers, many of whom make large purchases on a purchase-order basis.